CRI-103 gene therapy for dilated cardiomyopathy
Official title: CRI-103 gene therapy as Investigational New Drug for Dilated Cardiomyopathy
Funded at Cardiac Rsk3 Inhibitors, LLC · NIH-11292808 · Data updated 2026-11-12
A new gene therapy called CRI-103 aims to help adults with dilated cardiomyopathy by blocking a key heart-regulating protein interaction to prevent harmful heart remodeling.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cardiac Rsk3 Inhibitors, LLC NIH-funded |
| Lab location | 1 site (Los Altos, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,159,408 |
| NIH project number | 2R44HL167349-03 |
| Project ID | NIH-11292808 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with dilated cardiomyopathy who are eligible for the trial under protocol criteria.
✕Less likely to help
Patients whose condition does not meet the trial criteria or who experience adverse events could see no direct benefit.
What this research studies
This program is testing a gene therapy delivered by adeno-associated virus to disrupt a specific protein interaction in heart cells, with the goal of preventing or reversing damage seen in dilated cardiomyopathy. It builds on preclinical results showing improved heart function in animal models and aims to translate these findings toward human use. If successful, it could offer a novel treatment option beyond current therapies to reduce heart failure risk and arrhythmias in people with DCM.
Why it matters
Potential benefit: If successful, patients with dilated cardiomyopathy could experience better heart function and fewer complications.
How similar studies have gone: Preclinical studies in rodents and pigs showed reduced pathological remodeling and improved systolic function.
Where this research is happening
-
Cardiac Rsk3 Inhibitors, LLC
Los Altos, United States Active
Researchers
- Principal investigator: Cividini, Federico — Cardiac Rsk3 Inhibitors, LLC
- Study coordinator: Cividini, Federico
Related research
Other NIH-funded projects on the same topics.
-
Discovery of rare genetic variants linked to dilated cardiomyopathy using big biobank data
A large-scale genetic study will look for rare gene variants that affect dilated cardiomyopathy to improve how we diagnose and manage the condition.
-
Understanding how muscle ribosome mutations cause severe neonatal dilated cardiomyopathy and ways to treat it
This grant focuses on a rare genetic heart condition in newborns caused by mutations in a muscle-specific ribosomal protein, with hopes to find new ways to diagnose and treat it.
-
Unlocking how rare genetic changes cause dilated cardiomyopathy
A large study will look at genetic data from many people to understand which rare variants affect dilated cardiomyopathy and how this changes risk and treatment.
-
Role of Lmod2 in heart muscle and dilated cardiomyopathy
This NIH grant explores how a heart-specific protein (Lmod2) helps heart cells contract properly and how its problems can cause dilated cardiomyopathy in infants and children.
-
Targeting DNA Damage Pathways in LMNA-Related Heart Disease
A study to understand how damaged DNA and inflammatory signals contribute to dilated cardiomyopathy caused by LMNA mutations and explore therapies that can protect the heart.
-
Using miRNA to find new treatment paths for dilated cardiomyopathy
Researchers are studying heart-muscle disease (dilated cardiomyopathy) to discover miRNA-based clues that could lead to targeted therapies for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.